DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER (DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER).
Dextrose provides glucose for cellular metabolism, serving as a source of calories and energy. Lactated Ringer's solution supplies electrolytes (sodium, potassium, calcium, chloride) and lactate, which is metabolized to bicarbonate to buffer acidosis.
| Metabolism | Dextrose: metabolized via glycolysis and oxidative phosphorylation in tissues; lactate: converted to bicarbonate in the liver via gluconeogenesis. |
| Excretion | Renal: nearly 100% as intact dextrose and water; lactated Ringer's components (Na+, K+, Ca2+, Cl-, lactate) are excreted renally or metabolized (lactate to bicarbonate). Biliary/fecal: negligible. |
| Half-life | Terminal elimination half-life of dextrose is approximately 1.5-2 hours in healthy adults; clinically, redistribution occurs faster due to cellular uptake, but elimination depends on glucose homeostasis and renal function. |
| Protein binding | <5% bound; dextrose does not significantly bind to plasma proteins; lactate and electrolytes are minimally protein-bound. |
| Volume of Distribution | Approximately 0.2-0.25 L/kg (dextrose distributes mainly in extracellular fluid, but is rapidly taken up by cells); clinical interpretation: initial distribution to ECF, then intracellular uptake. |
| Bioavailability | Intravenous: 100% bioavailability; not applicable orally as the preparation is for IV use only. |
| Onset of Action | Intravenous: immediate onset of volume expansion and glucose provision (within minutes); metabolic effects begin within 1-2 minutes. |
| Duration of Action | Intravenous: volume effect lasts 1-2 hours; glucose effect lasts 30-60 minutes depending on infusion rate and metabolic demand. |
Intravenous infusion, typical adult dose is 1000 mL to 3000 mL per 24 hours, rate adjusted based on fluid and electrolyte needs.
| Dosage form | INJECTABLE |
| Renal impairment | Use caution in renal impairment; monitor fluid and electrolyte status. No specific GFR-based dose adjustment formula; adjust volume and rate based on renal function. |
| Liver impairment | No specific Child-Pugh based adjustment; monitor for fluid overload and electrolyte imbalances. |
| Pediatric use | Intravenous infusion, dose based on weight and clinical condition. Typical rate: 4-8 mg/kg/min of dextrose (equivalent to 5-10 mL/kg/hour of this solution for fluid maintenance, adjust as needed). |
| Geriatric use | Use with caution; monitor renal function and avoid fluid overload. Adjust infusion rate based on cardiovascular status and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER (DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER).
| Breastfeeding | Dextrose and lactated Ringer's components are normal constituents of breast milk. Exogenous administration at pharmacological doses is expected to result in minimal transfer. Dextrose is rapidly metabolized; its concentration in milk is not significantly increased. Lactate is a normal milk component. No specific M/P ratio available. Considered compatible with breastfeeding, but use only if clearly needed and monitor infant for signs of fluid or electrolyte imbalance if high volumes are administered. |
| Teratogenic Risk | Dextrose and lactated Ringer's solution components are generally considered low risk for teratogenicity. Dextrose is a normal constituent of blood and essential for fetal growth. No evidence of structural anomalies from intravenous administration. Lactated Ringer's components (sodium, chloride, potassium, calcium, lactate) are physiological and not associated with teratogenic effects. However, hyperglycemia from excessive dextrose may be associated with fetal macrosomia and neonatal hypoglycemia if maternal glucose control is poor. No trimester-specific risks beyond those related to maternal fluid and electrolyte balance. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hyperglycemia","Hypersensitivity to corn-derived products","Lactic acidosis","Severe hyperkalemia","Anuria"]
| Precautions | ["Monitor serum glucose and electrolytes","Use with caution in patients with renal impairment, heart failure, or hyperkalemia","Avoid in patients with lactic acidosis","Risk of fluid overload and hyperglycemia"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum glucose, electrolytes (sodium, potassium, calcium, chloride), and acid-base status periodically during prolonged infusion, especially in patients with impaired glucose tolerance or renal function. Monitor fetal heart rate and uterine activity if administered during labor. Assess maternal fluid balance to avoid fluid overload (pulmonary edema). In cases of hyperglycemia, monitor fetal growth via ultrasound to detect macrosomia. |
| Fertility Effects | No known adverse effects on fertility. Dextrose and lactated Ringer's are physiological solutions; there is no evidence of reproductive impairment when used as clinically indicated. High-dose or prolonged use that causes metabolic disturbances (e.g., hyperglycemia, electrolyte imbalances) might indirectly affect fertility, but this is not documented with standard dosing. |